287 related articles for article (PubMed ID: 24468315)
41. The diagnosis and management of NK/T-cell lymphomas.
Tse E; Kwong YL
J Hematol Oncol; 2017 Apr; 10(1):85. PubMed ID: 28410601
[TBL] [Abstract][Full Text] [Related]
42. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Kwong YL
J Clin Exp Hematop; 2011; 51(1):21-8. PubMed ID: 21628857
[TBL] [Abstract][Full Text] [Related]
43. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
44. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
45. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
[TBL] [Abstract][Full Text] [Related]
46. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.
Cai Q; Cai J; Fang Y; Young KH
Front Oncol; 2019; 9():386. PubMed ID: 31139570
[TBL] [Abstract][Full Text] [Related]
48. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
49. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E
Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133
[TBL] [Abstract][Full Text] [Related]
50. Extranodal natural killer/T-cell lymphoma: advances in the management.
Jaccard A; Hermine O
Curr Opin Oncol; 2011 Sep; 23(5):429-35. PubMed ID: 21743325
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E; Au-Yeung R; Kwong YL
Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
[No Abstract] [Full Text] [Related]
52. Management of advanced NK/T-cell lymphoma.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2014 Sep; 9(3):233-42. PubMed ID: 24924658
[TBL] [Abstract][Full Text] [Related]
53. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract][Full Text] [Related]
54. NK-Cell Lymphomas.
Chihara D; Oki Y
Cancer Treat Res; 2019; 176():163-184. PubMed ID: 30596218
[TBL] [Abstract][Full Text] [Related]
55. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
Yamaguchi M; Oguchi M; Suzuki R
Best Pract Res Clin Haematol; 2018 Sep; 31(3):315-321. PubMed ID: 30213402
[TBL] [Abstract][Full Text] [Related]
56. [Extranodal NK/T cell lymphoma, nasal type with local recurrence in the contralateral nasal cavity 15 years after initial sequential chemoradiotherapy].
Fujii T; Ohno N; Kitahara S; Kobayashi S; Sahara N; Sakamoto N; Arahira S; Matsunaga T
Rinsho Ketsueki; 2022; 63(3):229-232. PubMed ID: 35387938
[TBL] [Abstract][Full Text] [Related]
57. Novel treatment for early-stage nasal natural killer/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy.
Takahara M; Nagato T; Kishibe K; Ueda S; Komabayashi Y; Yamashina M; Takahashi K; Harabuchi Y
Hematol Oncol; 2017 Jun; 35(2):158-162. PubMed ID: 26563973
[TBL] [Abstract][Full Text] [Related]
58. A Rare Case of Aggressive Disseminated Nasal-Type Epstein-Barr Virus-Positive Extranodal Natural Killer/T-Cell Lymphoma with Bone Marrow Involvement.
Yee AC; Karim FW; Giashuddin SM; Grutman G
Am J Case Rep; 2023 Jun; 24():e939286. PubMed ID: 37384825
[TBL] [Abstract][Full Text] [Related]
59. How I treat NK/T-cell lymphomas.
Tse E; Kwong YL
Blood; 2013 Jun; 121(25):4997-5005. PubMed ID: 23652805
[TBL] [Abstract][Full Text] [Related]
60. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
Yamaguchi M
Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
